Thiacetazone: Time to call a halt? Considerations on the use of thiacetazone in African populations with a high prevalence of human immunodeficiency virus infection

Tubercle and Lung Disease

Volumn 77, Issue 1, 1996, Pages 27-29

  Elliott, A M ^a   Foster, S D ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; THIOACETAZONE; TUBERCULOSTATIC AGENT;

AFRICA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT COMPLIANCE; RASH; SHORT SURVEY; TUBERCULOSIS;

EID: 0030045332     PISSN: 09628479     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0962-8479(96)90071-4     Document Type: Note

References (24)

1. P Nunn D Kibuga S Gathua Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis Lancet 337 1991 627 630
2. AD Harries D Maher B Mvula D Nyangulu An audit of HIV testing and HIV-serostatus in tuberculosis patients, Blantyre, Malawi Tubercle Lung Dis 76 1995 413 417
3. East African/British Medical Research Councils Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis Third study. Second report 2nd edition Tubercle 61 1980 59 69
4. CJL Murray E Dejonghe HJ Chum Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries Lancet 338 1991 1305 1308
5. DJ Girling Adverse effects of antituberculous drugs Drugs 23 1982 56 74
6. JW Pape S Jean JL Ho A Hafner WD Johnson Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection Lancet 342 1993 268 272
7. C Whalen CR Horsburgh D Hom Accelerated course of Human Immunodeficiency Virus infection after tuberculosis American Journal of Respiratory and Critical Care Medicine 151 1995 129 135
8. P Nunn R Brindle L Carpenter Cohort study of Human Immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya: analysis of early (6-month) mortality Am Rev Respir Dis 146 1992 849 854
9. A Okwera C Whalen F Byekwaso Randomized trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans Lancet 344 1994 1323 1328
10. RJ Brindle PP Nunn W Githui BW Allen S Gathua P Waiyaki Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis Am Rev Respir Dis 147 1993 958 961
11. PP Eriki A Okwera T Aisu The influence of human immunodeficiency virus infection on tuberculosis in Kampala, Uganda Am Rev Respir Dis 143 1991 185 187
12. AL Pozniak GA MacLeod M Maxwell The influence of HIV status on single and multiple drug reactions to antituberculous therapy in Africa AIDS 6 1992 809 814
13. C Chintu C Luo G Bhat Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children Arch Dis Child 68 1993 655 668
14. AM Elliott B Halwiindi RJ Hayes The impact of Human Immunodeficiency Virus on response to treatment and recurrence rate in patients treated for tuberculosis: two-year follow-up of a cohort in Lusaka, Zambia J Trop Med Hyg 98 1995 9 21
15. MM Munthali DK Warndorff CW Koka JR Glynn FLM Salaniponi Thiacetazone reactions Transactions of the Royal Society of Tropical Medicine and Hygiene 89 1995 238
16. M Hawken P Nunn S Gathua Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya Lancet 342 1993 332 337
17. P Kelly A Buvé SD Foster Cutaneous reactions to thiacetazone in Zambia-implications for tuberculosis treatment strategies Transactions of the Royal Society of Tropical Medicine and Hygiene 88 1994 113 115
18. SD Foster P Kelly Use of thiacetazone (letter) Lancet 345 1995 62 63
19. D Wilkinson D Moore Use of thiacetazone (letter) Lancet 345 1995 63
20. M Temmerman J Ndinya Achola J Ambani P Piot The right not to know HIV-test results Lancet 345 1995 969 970
21. D Wilkinson High compliance tuberculosis treatment programme in a rural community Lancet 343 1994 647 648
22. PR Saunderson An economic evaluation of alternative programme designs for tuberculosis control in rural Uganda Social Science and Medicine 40 9 1995 1203 1212
23. HN Barnum Cost savings from alternative treatments for tuberculosis Social Science and Medicine 23 9 1986 847 850
24. P Tjiptoherijanto RM Joesoef Epidemiological model and costeffectiveness analysis of tuberculosis treatment programs in Indonesia AN Herrin PL Rosenfield Economics, Health, and Tropical Diseases 1988 University of the Philippines School of Economics Manila